Exscientia

Exscientia combines generative AI and active learning to design novel compounds and operates its own clinical-stage programs. Compared with Numerion Labs, Exscientia places heavier emphasis on end-to-end automation from target to clinic and maintains a larger disclosed pipeline. Its enterprise collaborations often involve milestone payments rather than pure software licensing.